<b>Gapping up/down:</b> DSW +8% and PLCE +5% after earnings, MJN +8% after M&A article; CPXX +435% after Phase 3 results; AAPL +1.6% after positive analyst note; TIF -2% after dg<br/><b>Gapping up <br/>In reaction to strong earnings/guidance: </b>SZYM +34.7%, (also signs a definitive 5-year global supply agreement w/ total revs of more than $200 w/ Unilever), BORN +23.5%, SKIS +19%, AMPH +17.4%, (light volume), ESI +15.6%, BIND +15.4%, BDE +14.6%, (light volume), GCAP +13.5%, BONT +13%, EGY +10.8%, INGN +8.7%, DSW +7.8%, FDS +5.9%, PERI +5.9%, PFSW +4.9%, PLCE +4.8%, HDS +4.3%, FSYS +4.1%, ARTX +3.5%, PETX +3.3%, CLLS +2.7%, VSLR +1%, EPRS +0.6%, BLCM +0.5%<br/><br/><b>M&A news: </b>OUTR +13.3% (to explore strategic and financial alternatives; increases quarterly dividend to $0.60/share from $0.30/share), MJN +8.1% (Betaville blog post reporting that MJN has received takeover interest from Danone (DANOY) and others)<br/><br/><b>Other news:</b> CPXX +434.5% (announces 'positive' results from Phase 3 trial of VYXEOS Liposome for Injection in patients with high-risk acute myeloid leukemia), OREX +35.7% (announces commercialization and distributorship agreement with valeant pharmaceuticals (VRX) for Mysimba for 18 Central and Eastern European countries & Turkey; announces strategic acquisition of all U.S. rights to Contrave, the branded anti-obesity prescription medicine), EXXI +21.4% (makes the interest payment due on its EPL Oil and Gas, Inc. 8.25% Senior Notes and reduces its borrowing base from $500 mln to $377.7 mln), CTIC +16% (provides update regarding the availability of pacritinib to certain patients with myelofibrosis), BPMC +11.5% (announces worldwide collaboration/exclusive license agreement with F. Hoffman-La Roche (RHHBY) to accelerate and expand its development of medicines in the field of cancer immunotherapy), APPY +7.6% (Terminates proposed transactions with Strand Life Sciences), AVEO +5.9% (disclosed SEC settlement update - Based on the progress in the process thus far - could potentially settle with the SEC for a total amount of $4 mln; also reported earnings), BCRX +5.4% (D.E. Shaw & Co discloses 5.1% passive stake), HBIO +4.3% (announces delay in filing Form 10-K), GWPH +2.3% (following 120% move higher Monday), RTK +2% (Rentech announces that GSO Capital Partners LP has agreed to provide an additional short-term liquidity of $6 mln ), AVP +1.6% (To reduce headcount by 2,500 positions as part of 3-year plan), ANTH +1% ( files for $100 mln mixed securities shelf offering)<br/><br/><b>Analyst comments: </b>CONN +2.8% (upgraded to Overweight from Equal Weight at a boutique firm), AAPL +1.6% Morgan Stanley out with a favorable view on iPhone demand in the March qtr) <br/><br/><b>Gapping down<br/>In reaction to disappointing earnings/guidance</b>: LINE -33.7%, VRX -17.9%, DCO -7.6%, MNKD -6.5%, (COO Juergen Martens resigns, Michael Castagna named Chief Commercial Officer, effective immediately ), ONTY -5.2%, NAVB -4.3%, TTEC -4%, MOMO -3.5%, FSM -2.6%, CFRX -1.7%, JMBA -1.6%, KANG -1%, LUK -0.9%, (Jefferies reports challenged Q1 results) PWR -0.8%, (appoints COO Earl Austin Jr to succeed Jim O'Neil as CEO effective immediately, reaffirms 2016 growth strategy & outlook), JASO -0.8%<br/><br/><b>M&A news: </b>PRTY -2.7% (Acquires Festival SA for ~$5 mln)<br/><br/><b>Select EU financial related names showing weakness:</b> SAN -3.4%, CS -3.1%, DB -2.7%, LYG -2%, BCS -1.4%, ING -1.2%, HSBC -0.9%<br/><br/><b>Select metals/mining stocks trading lower:</b> BBL -7.1%, MT -5%, FCX -4.7%, AKS -3.7%, CLF -3.3%, X -3%, AA -1.4%<br/><br/><b>Select oil/gas related names showing early weakness:</b> WLL -6%, SDRL -4.9%, PBR -4.6%, CHK -3.9%, BP -2.5%, MRO -2.5%, RIG -1.4%, TOT -1.4%<br/><br/><b>Other news:</b> IMMU -15.1% (To terminate the Phase 3 PANCRIT-1 trial with yttrium-90-labeled clivatuzumab tetraxetan in patients with metastatic pancreatic cancer), ALR -8.2% (will be unable to file its 2015 Form 10-K within the extension period, discloses receipt of a grand jury subpoena from the DOJ), TCON -5.4% ( initiates phase 1B study of TRC105 in patients with lung cancer), NVIV -4.6% (commences an underwritten public offering of common stock for unspecified amount), CNX -3.9% (Moody's downgrades CONSOL (CNX) to B2 with outlook negative and Moody's downgrades Natural Resource Partners (NRP) to B3 with outlook negative), CBPX -3% ( announces 4.5 mln share secondary common stock offering by selling shareholders & 900,000 share repurchase), ZYNE -2.5% (following 150% surge higher Monday), GLOG -1.7% (files for $600 mln mixed securities shelf offering )<br/><b><br/>Analyst comments: </b>DDD -8% (downgraded to Underweight from Neutral at JP Morgan), BHP -6.3% (downgraded to Underperform from Neutral at Macquarie), RIO -4.8% (downgraded to Equal Weight from Overweight at Morgan Stanley), HIBB -3.3% (downgraded to Sell from Neutral at Goldman), AZN -2.3% (downgraded to Hold from Buy at Jefferies), TIF -1.8% (downgraded to Neutral from Buy at Citigroup)<br/><br/>Briefing.com